Vol 64 No 3 (2019): Journal of the Chilean Chemical Society
Original Research Papers
A BRIEF REVIEW ON ANALYTICAL METHODS FOR ESTIMATION OF ISRADIPINE IN PHARMACEUTICAL FORMULATION AND BIOLOGICAL MATRICES
Published
October 30, 2019
Keywords
- Isradipine,
- hypertension,
- analytical methods,
- biological samples,
- pharmaceutical formulation
How to Cite
Marathe, S. R., Patil, A. S., Ganorkar, S. B., Chaudhari, S., & Shirkhedkar , A. A. (2019). A BRIEF REVIEW ON ANALYTICAL METHODS FOR ESTIMATION OF ISRADIPINE IN PHARMACEUTICAL FORMULATION AND BIOLOGICAL MATRICES. Journal of the Chilean Chemical Society, 64(3), 4565-4570. Retrieved from https://jcchems.com/index.php/JCCHEMS/article/view/1321
Abstract
Isradipine (ISRA) is a calcium channel blocking agent and a drug of the dihydropyridine (DHP) class. It is utilized for the treatment of hypertension and congestive
cardiac failure (CHF). It selectively binds with the calcium channel receptor with high compatibility and averts calcium alteration into cardiac and arterial smooth
muscle cells. ISRA employed to cure deliberate hypertension, used alone or in combination with thiazide diuretics. The present review article represents the
compilation and discussion of analytical methods published in the literature for estimation of ISRA in pharmaceutical samples and biological matrices consisting of
TLC/ densitometry, HPLC, UV-Visible method, Spectrofluorometry, Capillary Electrophoresis (CE), Polarography, Voltammetry and hyphenated techniques such
as LC-MS; LC-MS-MS, GC-MS, etc.
References
1. Makridakis S, DiNicolantonio JJ. Hypertension: empirical evidence and implications. Heart Open.1.1 (1):000048, (2014).
2. Chen R, Dharmarajan K, Kulkarni VT, Punnanithinont N, Gupta A, Bikdeli B, Mody PS, Ranasinghe I. Most important outcomes research papers on hypertension. Circulation: Cardiovascular Quality and Outcomes. 6(4):26-35, (2013).
3. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metabolism and Disposition. 28(2):125-30, (2013).
4. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatric Nephrology.15 (3-4):302-316, (2000).
5. The Merck Index, Merck and Co. New York.13: 937, (2001).
6. Nunez-Vergara LJ, Sunkel C, J. Pharm. Sci. 83.502–50, (1994).
7. Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. Journal of clinical hypertension.2 (3):28S-37S, (1986).
8. Fitton A, Benfield P. Isradipine. Drugs. 40(1):31-74, (1990).
9. Hof RP, Scholtysik G, Loutzenhiser R, Vuorela HJ, Neumann P. PN 200-110, A new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta. Journal of cardiovascular pharmacology. 6(3):399-406, (1984).
10. Pharmacopoeia B. The Stationary Office Medicinal and Pharmaceutical Substances (A–I). London. I: 1091-1092, (2005).
11. The United State Pharmacopeia/The National Formulary. The Official Compendia of Standard, 27:1051-1052, (2004).
12. Martindale Complete drug reference. An imprint of RPS Publishing pharmaceutical press. 35: 1319, (2007).
13. Al-Ghannam SM, Al-Olyan AM. Spectrophotometric determination of nicradipine and isradipine in pharmaceutical formulations. Chemical Industry and Chemical Engineering Quarterly. 15(2):69-76, (2009).
14. Katariya H, Prajapati J. Development and validation of UV Spectrophotometric method for determination of isradipine loaded into solid lipid nanoparticles. International Journal of Pharmaceutical Sciences Review and Research. 20(2):162-166, (2013).
15. Rao RN, Nagaraju P, Srinivasulu C, Radhakrishnamurthy P, Sireesha D, Bhaskar SU. UV Spectrophotometric methods for the determination of lercanidipine and isradipine in bulk and pharmaceutical formulations. Asian Journal of Chemistry. 16(3):1950, (2004).
16. Al-Ghannam S, Al-Olyan A. Spectrofluorometric determination of nicardipine, nifedipine and isradipine in pharmaceutical preparations and biological fluids. Open Chemistry. 6(2):222-8, (2008).
17. Vera k, 2016, what is HPLC, Chemistry view magazine, Wiley-VCH and chem. pub so Europe. (2016).
18. Elena K, Roy E, Peter S, Neil M. Chromatographic sciences series of handbook of HPLC, HPLC introduction. Marcel dekker, Inc.78:499-531, (2003-04).
19. Yuvi KK, Rosario L. HPLC for pharmaceutical scientists, Introduction HPLC. John willey and sons, Inc. 3-10, (2007).
20. Synder LR, Kirkland JJ, Glajch JL. Practical HPLC method development, Application of HPLC. A john willey and son, Inc, 2:59-67, (1997).
21. Chaitanya KK, Sankar DG, Israel DS, Lakshmi AV, Kumar CHN, Chaitanya KK. Isocratic-Reverse Phase Liquid Chromatographic method for the quantification of isradipine by UV detection in tablets.Scholars Research Library 1(4):220–227, (2012).
22. Aswini GL, Babu DYR, Surekha ML, Swamy GK. Development and validation of Isradipine in Bulk and in its Pharmaceutical formulation by RP-HPLC Method, International Research Journal of Pharmacy. 3(9):131–133, (2012).
23. M Younus, Pasha SI, Siddiq M, Lakshmi AP, 2012.RP-HPLC Method Development for estimation of isradipine in tablet dosage form. Asian journal of pharmaceutical and clinical research. 6(1):140-142, (2012).
24. Gopal PNV, Shrinivas VDN, Padma SVN. RP-HPLC Estimation of Isradipine in Pharmaceutical Dosage Forms, Asian journal of chemistry. 20(8):6097–6102, (2008).
25. Rao RN, Srinivasulu PNC, Reddy VS, Suresh V, Jitendra P. HPLC method for the estimation of isradipine in pharmaceutical dosage forms, International Journal Chemical Science 2(3):345-350, (2004).
26. Simoes RA, de Oliveira AR, Bonato PS. Hollow fiber-based liquid-phase microextraction (HF-LPME) of isradipine and its main metabolite followed by Chiral HPLC analysis: application to an in vitro biotransformation study. Analytical and bio-analytical chemistry.399 (7):2435-43, (2011).
27. Takamura K, Kusu F, Abdel‐Wadood H, El‐Rabbat N, Saleh G, Refaat I. Redox properties of isradipine and its electrochemical detection in the HPLC determination of the compound in human serum. Biomedical Chromatography. 14(7):453-8, (2000).
28. Al-Suwayeh SA. Quick, simple, and sensitive HPLC method for determination of isradipine in plasma and its application in pharmacokinetic studies. Analytical letters. 35(7):1205-13, (2002).
29. Bidouil S, Dubois J, Hanocq M. Isocratic high-performance liquid chromatographic method for the separation of isradipine and its main metabolites: Application to in vitro metabolization by h3A4/OR cells. Journal of Chromatography B: Biomedical Sciences and Applications. 693(2):359-66, (1997).
30. Oravcova J, Sojkova D, Bencsikova E, Bohov P, Trnovec T. Stereoselective binding of isradipine to human plasma proteins. Chirality. 7(3):167-72, (1995).
31. Rask HS, Angelo HR, Christensen HR. Enantioselective determination of isradipine in human serum using chiral stationary phase liquid chromatography and gas chromatography with nitrogen selective detection. Chirality. 10(9):808-12, (1998).
32. Mielcarek J, Daczkowska E. Photodegradation of inclusion complexes of isradipine with methyl-β-cyclodextrin. Journal of pharmaceutical and biomedical analysis. 21(2):393-8, (1999).
33. Elghany MF, Elzeany BE, Elkawy MA, Stewart JT. A stability indicating high performance liquid chromatographic assay of isradipine in pharmaceutical preparations. Analytical letters. 29(7):1157-65, (1996).
34. Christensen HR, Angelo HR, Skajaa K. Determination of isradipine and its pyridine metabolite in serum by capillary column gas chromatography with nitrogen-selective detection. Journal of Chromatography B: Biomedical Sciences and Applications. 574(1):161-5, (1992).
35. Patel KN, Patel JK, Patel MP, Rajput GC, Patel HA. Introduction to hyphenated techniques and their applications in pharmacy. Pharmaceutical methods. 1(1):2-13, (2010).
36. Thamizhaban D, Rani TG, Pravallika P. A Review on hyphenated separaration techniques used in pharmaceutical analysis, IOSR Journal of pharmacy and biological sciences, II: 65-74, (2016).
37. Jean C, Laplanche R. Assay of isradipine and of its major metabolites in biological fluids by capillary gas chromatography and chemical ionization mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications. 428:61-9, (1998).
38. Maurer HH, Arlt JW. Screening procedure for detection of dihydropyridine calcium channel blocker metabolites in urine as part of a systematic toxicological analysis procedure for acidic compounds by gas chromatography-mass spectrometry after extractive methylation. Journal of analytical toxicology. 23(2):73-80, (1999).
39. Baranda AB, Alonso RM, Jiménez RM, Weinmann W. Instability of calcium channel antagonists during sample preparation for LC–MS–MS analysis of serum samples. Forensic science international. 156(1):23-34, (2006).
40. Bartlett MG, Spell JC, Mathis PS, Elgany MF, El Zeany BE, Elkawy MA, Stewart JT. Determination of degradation products from the calcium-channel blocker isradipine. Journal of pharmaceutical and biomedical analysis. 18(3):335-45, (1998).
41. Park JH, Park YS, Rhim SY, Jhee OH, Kim SH, Yang SC, Lee MH, Shaw LM, Kang JS. Quantification of isradipine in human plasma using LC–MS/MS for pharmacokinetic and bioequivalence study. Journal of Chromatography B. 877(1-2):59-64, (2009).
42. Yang X, Xu H, Gan J, Li L, Li J, Jin Y, Yuan B. Quantitative determination of isradipine in dog plasma by an ultra performance liquid chromatography–tandem mass spectrometry method. Asian Journal of Pharmaceutical Sciences. 8(5):312-7, (2013).
43. Belal F, Al-Majed AA, Julkhuf S. Anodic Polaroqraphic Determination of isradipine in Pharmaceutical Formulations. Scientia Pharmaceutica. 72(2):131-42, (2004).
44. Belal F, Al-Majed A, Julkhuf S. Voltammetric determination of isradipine in dosage forms and spiked human plasma and urine. Journal of pharmaceutical and biomedical analysis. 31(5):989-98, (2003).
45. Aguiar FA, de Gaitani CM, Borges KB. Capillary electrophoresis method for the determination of isradipine enantiomers: stability studies and pharmaceutical formulation analysis. Electrophoresis. 32(19):2673-82, (2011).
2. Chen R, Dharmarajan K, Kulkarni VT, Punnanithinont N, Gupta A, Bikdeli B, Mody PS, Ranasinghe I. Most important outcomes research papers on hypertension. Circulation: Cardiovascular Quality and Outcomes. 6(4):26-35, (2013).
3. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metabolism and Disposition. 28(2):125-30, (2013).
4. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatric Nephrology.15 (3-4):302-316, (2000).
5. The Merck Index, Merck and Co. New York.13: 937, (2001).
6. Nunez-Vergara LJ, Sunkel C, J. Pharm. Sci. 83.502–50, (1994).
7. Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. Journal of clinical hypertension.2 (3):28S-37S, (1986).
8. Fitton A, Benfield P. Isradipine. Drugs. 40(1):31-74, (1990).
9. Hof RP, Scholtysik G, Loutzenhiser R, Vuorela HJ, Neumann P. PN 200-110, A new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta. Journal of cardiovascular pharmacology. 6(3):399-406, (1984).
10. Pharmacopoeia B. The Stationary Office Medicinal and Pharmaceutical Substances (A–I). London. I: 1091-1092, (2005).
11. The United State Pharmacopeia/The National Formulary. The Official Compendia of Standard, 27:1051-1052, (2004).
12. Martindale Complete drug reference. An imprint of RPS Publishing pharmaceutical press. 35: 1319, (2007).
13. Al-Ghannam SM, Al-Olyan AM. Spectrophotometric determination of nicradipine and isradipine in pharmaceutical formulations. Chemical Industry and Chemical Engineering Quarterly. 15(2):69-76, (2009).
14. Katariya H, Prajapati J. Development and validation of UV Spectrophotometric method for determination of isradipine loaded into solid lipid nanoparticles. International Journal of Pharmaceutical Sciences Review and Research. 20(2):162-166, (2013).
15. Rao RN, Nagaraju P, Srinivasulu C, Radhakrishnamurthy P, Sireesha D, Bhaskar SU. UV Spectrophotometric methods for the determination of lercanidipine and isradipine in bulk and pharmaceutical formulations. Asian Journal of Chemistry. 16(3):1950, (2004).
16. Al-Ghannam S, Al-Olyan A. Spectrofluorometric determination of nicardipine, nifedipine and isradipine in pharmaceutical preparations and biological fluids. Open Chemistry. 6(2):222-8, (2008).
17. Vera k, 2016, what is HPLC, Chemistry view magazine, Wiley-VCH and chem. pub so Europe. (2016).
18. Elena K, Roy E, Peter S, Neil M. Chromatographic sciences series of handbook of HPLC, HPLC introduction. Marcel dekker, Inc.78:499-531, (2003-04).
19. Yuvi KK, Rosario L. HPLC for pharmaceutical scientists, Introduction HPLC. John willey and sons, Inc. 3-10, (2007).
20. Synder LR, Kirkland JJ, Glajch JL. Practical HPLC method development, Application of HPLC. A john willey and son, Inc, 2:59-67, (1997).
21. Chaitanya KK, Sankar DG, Israel DS, Lakshmi AV, Kumar CHN, Chaitanya KK. Isocratic-Reverse Phase Liquid Chromatographic method for the quantification of isradipine by UV detection in tablets.Scholars Research Library 1(4):220–227, (2012).
22. Aswini GL, Babu DYR, Surekha ML, Swamy GK. Development and validation of Isradipine in Bulk and in its Pharmaceutical formulation by RP-HPLC Method, International Research Journal of Pharmacy. 3(9):131–133, (2012).
23. M Younus, Pasha SI, Siddiq M, Lakshmi AP, 2012.RP-HPLC Method Development for estimation of isradipine in tablet dosage form. Asian journal of pharmaceutical and clinical research. 6(1):140-142, (2012).
24. Gopal PNV, Shrinivas VDN, Padma SVN. RP-HPLC Estimation of Isradipine in Pharmaceutical Dosage Forms, Asian journal of chemistry. 20(8):6097–6102, (2008).
25. Rao RN, Srinivasulu PNC, Reddy VS, Suresh V, Jitendra P. HPLC method for the estimation of isradipine in pharmaceutical dosage forms, International Journal Chemical Science 2(3):345-350, (2004).
26. Simoes RA, de Oliveira AR, Bonato PS. Hollow fiber-based liquid-phase microextraction (HF-LPME) of isradipine and its main metabolite followed by Chiral HPLC analysis: application to an in vitro biotransformation study. Analytical and bio-analytical chemistry.399 (7):2435-43, (2011).
27. Takamura K, Kusu F, Abdel‐Wadood H, El‐Rabbat N, Saleh G, Refaat I. Redox properties of isradipine and its electrochemical detection in the HPLC determination of the compound in human serum. Biomedical Chromatography. 14(7):453-8, (2000).
28. Al-Suwayeh SA. Quick, simple, and sensitive HPLC method for determination of isradipine in plasma and its application in pharmacokinetic studies. Analytical letters. 35(7):1205-13, (2002).
29. Bidouil S, Dubois J, Hanocq M. Isocratic high-performance liquid chromatographic method for the separation of isradipine and its main metabolites: Application to in vitro metabolization by h3A4/OR cells. Journal of Chromatography B: Biomedical Sciences and Applications. 693(2):359-66, (1997).
30. Oravcova J, Sojkova D, Bencsikova E, Bohov P, Trnovec T. Stereoselective binding of isradipine to human plasma proteins. Chirality. 7(3):167-72, (1995).
31. Rask HS, Angelo HR, Christensen HR. Enantioselective determination of isradipine in human serum using chiral stationary phase liquid chromatography and gas chromatography with nitrogen selective detection. Chirality. 10(9):808-12, (1998).
32. Mielcarek J, Daczkowska E. Photodegradation of inclusion complexes of isradipine with methyl-β-cyclodextrin. Journal of pharmaceutical and biomedical analysis. 21(2):393-8, (1999).
33. Elghany MF, Elzeany BE, Elkawy MA, Stewart JT. A stability indicating high performance liquid chromatographic assay of isradipine in pharmaceutical preparations. Analytical letters. 29(7):1157-65, (1996).
34. Christensen HR, Angelo HR, Skajaa K. Determination of isradipine and its pyridine metabolite in serum by capillary column gas chromatography with nitrogen-selective detection. Journal of Chromatography B: Biomedical Sciences and Applications. 574(1):161-5, (1992).
35. Patel KN, Patel JK, Patel MP, Rajput GC, Patel HA. Introduction to hyphenated techniques and their applications in pharmacy. Pharmaceutical methods. 1(1):2-13, (2010).
36. Thamizhaban D, Rani TG, Pravallika P. A Review on hyphenated separaration techniques used in pharmaceutical analysis, IOSR Journal of pharmacy and biological sciences, II: 65-74, (2016).
37. Jean C, Laplanche R. Assay of isradipine and of its major metabolites in biological fluids by capillary gas chromatography and chemical ionization mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications. 428:61-9, (1998).
38. Maurer HH, Arlt JW. Screening procedure for detection of dihydropyridine calcium channel blocker metabolites in urine as part of a systematic toxicological analysis procedure for acidic compounds by gas chromatography-mass spectrometry after extractive methylation. Journal of analytical toxicology. 23(2):73-80, (1999).
39. Baranda AB, Alonso RM, Jiménez RM, Weinmann W. Instability of calcium channel antagonists during sample preparation for LC–MS–MS analysis of serum samples. Forensic science international. 156(1):23-34, (2006).
40. Bartlett MG, Spell JC, Mathis PS, Elgany MF, El Zeany BE, Elkawy MA, Stewart JT. Determination of degradation products from the calcium-channel blocker isradipine. Journal of pharmaceutical and biomedical analysis. 18(3):335-45, (1998).
41. Park JH, Park YS, Rhim SY, Jhee OH, Kim SH, Yang SC, Lee MH, Shaw LM, Kang JS. Quantification of isradipine in human plasma using LC–MS/MS for pharmacokinetic and bioequivalence study. Journal of Chromatography B. 877(1-2):59-64, (2009).
42. Yang X, Xu H, Gan J, Li L, Li J, Jin Y, Yuan B. Quantitative determination of isradipine in dog plasma by an ultra performance liquid chromatography–tandem mass spectrometry method. Asian Journal of Pharmaceutical Sciences. 8(5):312-7, (2013).
43. Belal F, Al-Majed AA, Julkhuf S. Anodic Polaroqraphic Determination of isradipine in Pharmaceutical Formulations. Scientia Pharmaceutica. 72(2):131-42, (2004).
44. Belal F, Al-Majed A, Julkhuf S. Voltammetric determination of isradipine in dosage forms and spiked human plasma and urine. Journal of pharmaceutical and biomedical analysis. 31(5):989-98, (2003).
45. Aguiar FA, de Gaitani CM, Borges KB. Capillary electrophoresis method for the determination of isradipine enantiomers: stability studies and pharmaceutical formulation analysis. Electrophoresis. 32(19):2673-82, (2011).
